IL5 and coronary artery disorder: Moreover, eosinophils that include IL-5 receptors have been identified in thrombi, providing biological plausibility of these associations with risk of CHD.16 Monoclonal antibodies, such as benralizumab that target IL-5 receptor and lower plasma levels of IL-5, have been shown to be effective for the relief of symptomatic eosinophilic asthma17 18 and prompted interest in exploring the potential relevance of this pathway for CHD.